Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 04 Aug 2021 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.
- 21 Oct 2020 Planned End Date changed from 6 Oct 2020 to 31 Dec 2020.